StockNews.AI
NUWE
StockNews.AI
3 hrs

Nuwellis, Inc. Participates in a Virtual Investor “What This Means” Segment

1. Nuwellis received a $3 million NIH grant for pediatric CRRT device. 2. The grant aims to accelerate the development of Vivian™, a new medical device. 3. Nuwellis is enhancing its software and firmware for broader portfolio strengthening. 4. Company prioritizes innovation in fluid management solutions for critically ill patients.

3m saved
Insight
Article

FAQ

Why Bullish?

Grant funding is a positive indicator of growth and innovation potential, similar to other medical device companies that saw stock price increases after receiving research grants.

How important is it?

The NIH grant's significance in funding could signal future product viability and market confidence in Nuwellis' innovations.

Why Long Term?

The NIH grant supports long-term product development, with potential revenue growth projected beyond the immediate term.

Related Companies

KBTAXNXISRGMDTBSX
Watch the “What This Means” segment here MINNEAPOLIS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company delivering fluid management solutions for critically ill patients, today announced that it participated in a Virtual Investor “What This Means” segment.  For the segment, Ryan Marthaler, Vice President of Product Marketing & Business Development of Nuwellis, discussed the Company’s recent news release announcing that the National Institutes of Health (NIH) has awarded an approximately $3 million multi-year grant to its development partner, Koronis Biomedical Technologies Corporation (KBT). The NIH-supported program will accelerate Vivian™, Nuwellis’ dedicated pediatric continuous renal replacement therapy (CRRT) device in development for patients under 20 kilograms, and advance core software and firmware that strengthen the company’s broader portfolio. The Virtual Investor “What this Means” segment featuring Nuwellis is now available here.  About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or X, formerly known as Twitter. For further information, please contact: Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775nuwe@jtcir.com Media Contact: Leah McMullenDirector of CommunicationsLeah.mcmullen@nuwellis.com

Related News